As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > ORGANIZATION
ORGANIZATION
- JMA Chief Pushes September 2019 Drug Price Announcement for Ad-Hoc Revision
December 27, 2018
- Use of Generics and Formulary Would Reduce Drug Expenditure by 38%: Payer Estimate
December 27, 2018
- March Announcement of NHI Price List “Not an Option”, Says Wholesaler Group
December 25, 2018
- October 2019 Drug Price Revision a Relief for JPMA: Official
December 25, 2018
- Pharma Companies Mull Use of Tohoku University’s Database for Drug Discovery: JPMA Official
December 18, 2018
- Lilly’s Jonsson to Stay as PhRMA Japan Chief
December 13, 2018
- 9 EFPIA Companies Reviewed Headcount Planning after Drug Pricing Overhaul: Survey
December 5, 2018
- JPMA Chief Warns against Japan Govt’s Short-Sighted Budgeting, Calls for Longer-Term View on Innovation
November 26, 2018
- 8 Infectious Disease-Related Societies Launch New Organization to Combat Drug-Resistance Problem
November 12, 2018
- 7 EFPIA Companies Revised R&D Strategies after April Pricing Overhaul: Survey
November 9, 2018
- Wrong Policies Could Drive Investments Out of Japan amid China’s Rise, PhRMA Int’l Advocacy Chief Warns
November 6, 2018
- Japan, US, Europe Trade Groups Stress Importance of Drug Discovery, Call for “Angel Cycle”
November 5, 2018
- Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
October 29, 2018
- EFPIA Japan Chief Eyes New Funding Model for Innovative but Pricey Therapies
October 26, 2018
- Japan Wholesaler Chief Suzuki Becomes IFPW Chairman
October 16, 2018
- Asian Consortium for Natural Substance-Based Drug Discovery to Leverage Asian Natural Resources, Japanese Technologies
October 15, 2018
- Japan Drug Industry Vows Further Efforts in Academic Collaboration after Honjo’s Nobel Prize
October 3, 2018
- Generic Use Rate at 72.2% in April-June: JGA
October 1, 2018
- October 2019 “Only Option” for Drug Price Revision Tied to Sales Tax Hike: New FPMAJ Chief
September 25, 2018
- 19 Companies Join JPMA Task Force on Quality Evaluation of Nucleic Acid Therapeutics
September 18, 2018
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…